Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Amarantus Bioscience Holdings (AMBS) Message Board

The face value of the notes owed I believe was 17-

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 30066
(Total Views: 358)
Posted On: 03/29/2017 11:09:32 AM
Posted By: investorxc
The face value of the notes owed I believe was 17-18 million, but the actual payoff amount was much higher. All Aboard had estimated it at about 28 million at one point. It was certainly more than 20 million. So assuming that Cutanogen will be the holding co for ESS, then they are giving up 35% ownership of ESS and about 63 million shares in AVDX to forgive about 12 million + in debt.

I think this is a good deal and the best option they had. ESS was valued at about 30 million by Jason N when they first bought it, but remember they only paid about 12 million for ESS, so 35% of that amount is just $4 million. Not sure what they had invested in the DX assets? I see this as taking 2 steps backwards to (hopefully) take 3 steps forward. I always thought it would make the most sense to sell off assets rather than try to raise 20 million when you are at 5 cents a share. A new lender could end up owning the entire company.

I'm surprised by the low volume today- I guess an 8K just doesn't have the effect a pr does. When they get the funding and the notes are taken out, there will be a pr then and I expect we will see a nice run. My prediction in the long term is that once SeD injects the additional assets, they will change the name of the company, fire GC and uplist. The question is how many shares AMBS will need to issue for these additional assets. Hopefully when the notes are taken out (but before the assets are acquired) the share price will be a good bit higher which will limit the dilution. If the promissory notes were converted today, 40 million shares, we would be at 118 million total, so not that bad.


(2)
(0)




Amarantus Bioscience Holdings (AMBS) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us